MedTrace Logo

Princess® RICH for the Correction of Fine Lines

NCT03923634 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 102

Last updated 2024-12-10

No results posted yet for this study

Summary

Eligible subjects deemed by the treating physician to have sufficient severity to merit treatment of either their lateral canthal lines (LCL) or perioral rhytids (PR) or both will be treated with Princess® RICH at the Baseline visit and at week 3 and 6.

Conditions

  • Lateral Canthal Lines
  • Perioral Rhytids

Interventions

DEVICE

Princess® RICH

Princess® RICH is injected into lateral canthal lines and/or perioral rhytids

Sponsors & Collaborators

  • Croma-Pharma GmbH

    lead INDUSTRY

Principal Investigators

  • Monika Sulovsky, MD · Yuvell

  • Daisy Kopera, MD · Medizinische Universität Graz- Klinikum für Dermatologie und Venerologie

  • Thomas Rappl, MD · MaRa-Medical Aesthetic Research Academy

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-16
Primary Completion
2019-04-29
Completion
2019-10-22

Countries

  • Austria

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03923634 on ClinicalTrials.gov